Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-lactamase-producing escherichia coli in a foreign-body infection model

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1421-1427

  Corvec, Stéphane ^a,b   Tafin, Ulrika Furustrand ^a   Betrisey, Bertrand ^a   Borens, Olivier ^a   Trampuz, Andrej ^a,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; FOSFOMYCIN; GENTAMICIN; TIGECYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FOREIGN BODY; FOREIGN BODY INFECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROCALORIMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BIOFILMS; COLISTIN; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOREIGN BODIES; FOSFOMYCIN; GENTAMICINS; GUINEA PIGS; MALE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; POLYTETRAFLUOROETHYLENE; PROSTHESES AND IMPLANTS;

EID: 84874077677     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01718-12     Document Type: Article

References (57)

1. Sendi P, Zimmerli W. 2011. Challenges in periprosthetic knee-joint infection. Int. J. Artif. Organs 34:947-956.
2. Zimmerli W, Moser C. 2012. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol. Med. Microbiol. 65: 158-168.
3. Moran E, Byren I, Atkins BL. 2010. The diagnosis and management of prosthetic joint infections. J. Antimicrob. Chemother. 65(Suppl. 3):iii45- iii54.
4. Trampuz A, Widmer AF. 2006. Infections associated with orthopedic implants. Curr. Opin. Infect. Dis. 19:349 -356.
5. Martinez-Pastor JC, Munoz-Mahamud E, Vilchez F, Garcia-Ramiro S, Bori G, Sierra J, Martinez JA, Font L, Mensa J, Soriano A. 2009. Outcome of acute prosthetic joint infections due to gram-negative bacilli treated with open debridement and retention of the prosthesis. Antimicrob. Agents Chemother. 53:4772- 4777.
6. Hsieh PH, Lee MS, Hsu KY, Chang YH, Shih HN, Ueng SW. 2009. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin. Infect. Dis. 49:1036 -1043.
7. Martinez-Pastor JC, Vilchez F, Pitart C, Sierra JM, Soriano A. 2010. Antibiotic resistance in orthopaedic surgery: acute knee prosthetic joint infections due to extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Eur. J. Clin. Microbiol. Infect. Dis. 29:1039 -1041.
8. Legout L, Senneville E, Stern R, Yazdanpanah Y, Savage C, Roussel- Delvalez M, Rosele B, Migaud H, Mouton Y. 2006. Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepimefluoroquinolone combination. Clin. Microbiol. Infect. 12:1030 -1033.
9. Paladino JA, Callen WA. 2003. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters. J. Antimicrob. Chemother. 51(Suppl 1):43- 47.
10. Sendi P, Frei R, Maurer TB, Trampuz A, Zimmerli W, Graber P. 2010. Escherichia coli variants in periprosthetic joint infection: diagnostic challenges with sessile bacteria and sonication. J. Clin. Microbiol. 48:1720- 1725.
11. Cremet L, Corvec S, Bemer P, Bret L, Lebrun C, Lesimple B, Miegeville AF, Reynaud A, Lepelletier D, Caroff N. 2012. Orthopaedic-implant infections by Escherichia coli: molecular and phenotypic analysis of the causative strains. J. Infect. 64:169 -175.
12. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Canica MM, Park YJ, Lavigne JP, Pitout J, Johnson JR. 2008. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J. Antimicrob. Chemother. 61:273-281.
13. Clermont O, Lavollay M, Vimont S, Deschamps C, Forestier C, Branger C, Denamur E, Arlet G. 2008. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J. Antimicrob. Chemother. 61:1024 -1028.
14. Cooper MA, Shlaes D. 2011. Fix the antibiotics pipeline. Nature 472:32.
15. Pogue JM, Marchaim D, Kaye D, Kaye KS. 2011. Revisiting "older" antimicrobials in the era of multidrug resistance. Pharmacotherapy. 31: 912-921.
16. Raz R. 2012. Fosfomycin: an old-new antibiotic. Clin. Microbiol. Infect. 18:4 -7.
17. Yahav D, Farbman L, Leibovici L, Paul M. 2012. Colistin: new lessons on an old antibiotic. Clin. Microbiol. Infect. 18:18 -29.
18. Carlet J, Mainardi JL. 2012. Antibacterial agents: back to the future? Can we live with only colistin, co-trimoxazole and fosfomycin? Clin. Microbiol. Infect. 18:1-3.
19. Cai Y, Fan Y, Wang R, An MM, Liang BB. 2009. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. J. Antimicrob. Chemother. 64:563-566.
20. Schintler MV, Traunmuller F, Metzler J, Kreuzwirt G, Spendel S, Mauric O, Popovic M, Scharnagl E, Joukhadar C. 2009. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J. Antimicrob. Chemother. 64:574- 578.
21. Miro JM, Entenza JM, Del Rio A, Velasco M, Castaneda X, Garcia de la Maria C, Giddey M, Armero Y, Pericas JM, Cervera C, Mestres CA, Almela M, Falces C, Marco F, Moreillon P, Moreno A, the Hospital Clinic Experimental Endocarditis Study Group. 2012. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillinsusceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 56:4511- 4515.
22. Entenza JM, Moreillon P. 2009. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 34:8.e1-8e.9. doi:10.1016/j.ijantimicag.2008.11.006.
23. Azzopardi EA, Ferguson EL, Thomas DW. 2012. Colistin past and future: a bibliographic analysis. J. Crit. Care [Epub ahead of print.] doi:10 .1016/j.jcrc.2012.04.008.
24. Furustrand Tafin U, Corvec S, Betrisey B, Zimmerli W, Trampuz A. 2012. Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model. Antimicrob. Agents Chemother. 56:1885-1891.
25. John AK, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, Trampuz A. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719 -2724.
26. Zimmerli W, Frei R, Widmer AF, Rajacic Z. 1994. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J. Antimicrob. Chemother. 33:959 -967.
27. Furustrand Tafin U, Majic I, Zalila Belkhodja C, Betrisey B, Corvec S, Zimmerli W, Trampuz A. 2011. Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model. Antimicrob. Agents Chemother. 55:4821- 4827.
28. Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A. 2009. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob. Agents Chemother. 53:1142-1148.
29. Clinical Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that growth aerobically; approved guideline-ninth edition. M07-A9. Clinical Laboratory Standards Institute, Wayne, PA.
30. Clinical Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline-first edition. M26-A. Clinical Laboratory Standards Institute, Wayne, PA.
31. Astasov-Frauenhoffer M, Braissant O, Hauser-Gerspach I, Daniels AU, Weiger R, Waltimo T. 2012. Isothermal microcalorimetry provides new insights into biofilm variability and dynamics. FEMS Microbiol. Lett. 337: 31-37.
32. Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Georgopoulos A, Burgmann H. 2011. Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55:931-933.
33. Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Lagler H, Georgopoulos A, Burgmann H. 2011. Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrobial. Agents Chemother. 55:4999 -5003.
34. Pachon-Ibanez ME, Ribes S, Dominguez MA, Fernandez R, Tubau F, Ariza J, Gudiol F, Cabellos C. 2011. Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin. Eur. J. Clin. Microbiol. Infect. Dis. 30:89 -95.
35. Ribes S, Taberner F, Domenech A, Cabellos C, Tubau F, Linares J, Viladrich PF, Gudiol F. 2006. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 57:931-936.
36. Niska JA, Shahbazian JH, Ramos RI, Pribaz JR, Billi F, Francis KP, Miller LS. 2012. Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice. Antimicrob. Agents Chemother. 56: 2590-2597.
37. Yin LY, Lazzarini L, Li F, Stevens CM, Calhoun JH. 2005. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J. Antimicrob. Chemother. 55:995-1002.
38. Marchand S, Lamarche I, Gobin P, Couet W. 2010. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J. Antimicrob. Chemother. 65:1753-1758.
39. Garrigos C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. 2013. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign body infection by methicillin resistant Staphylococcus aureus (MRSA). Antimicrob. Agents Chemother. 57:606-610.
40. Trampuz A, Piper KE, Jacobson MJ, Hanssen AD, Unni KK, Osmon DR, Mandrekar JN, Cockerill FR, Steckelberg JM, Greenleaf JF, Patel R. 2007. Sonication of removed hip and knee prostheses for diagnosis of infection. N. Engl. J. Med. 357:654-663.
41. von Ah U, Wirz D, Daniels AU. 2009. Isothermal micro calorimetry-a new method for MIC determinations: results for 12 antibiotics and reference strains of E. coli and S. aureus. BMC Microbiol. 9:106.
42. Falagas ME, Karageorgopoulos DE, Nordmann P. 2011. Therapeutic options for infections with Enterobacteriaceae producing carbapenemhydrolyzing enzymes. Future Microbiol. 6:653- 666.
43. Zimmerli W, Trampuz A, Ochsner PE. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.
44. Nation RL, Li J. 2009. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22:535-543.
45. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. 2009. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents 34:506 -515.
46. Cobo J, Morosini MI, Pintado V, Tato M, Samaranch N, Baquero F, Canton R. 2008. Use of tigecycline for the treatment of prolonged bacte-remia due to a multiresistant VIM-1 and SHV-12 beta-lactamaseproducing Klebsiella pneumoniae epidemic clone. Diagn. Microbiol. Infect. Dis. 60:319 -322.
47. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. 2003. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:905-909.
48. Wareham DW, Gordon NC, Hornsey M. 2011. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 66:1047-1051.
49. Couet W, Gregoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose ofCMSin young healthy volunteers. Clin. Pharmacol. Ther. 89:875- 879.
50. Tang HJ, Chen CC, Cheng KC, Toh HS, Su BA, Chiang SR, Ko WC, Chuang YC. 2012. In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms. J. Antimicrob. Chemother. 67:944 -950.
51. Blaser J, Vergeres P, Widmer AF, Zimmerli W. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134 -1139.
52. Widmer AF, Wiestner A, Frei R, Zimmerli W. 1991. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in devicerelated infections. Antimicrob. Agents Chemother. 35:741-746.
53. Craig WA. 1993. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J. Antimicrob. Chemother. 31(Suppl D):149 -158.
54. Rodriguez-Martinez JM, Ballesta S, Pascual A. 2007. Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and cotrimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms. Int. J. Antimicrob. Agents 30:366 -368.
55. Mikuniya T, Kato Y, Ida T, Maebashi K, Monden K, Kariyama R, Kumon H. 2007. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J. Infect. Chemother. 13:285-290.
56. Marchese A, Bozzolasco M, Gualco L, Debbia EA, Schito GC, Schito AM. 2003. Effect of fosfomycin alone and in combination with Nacetylcysteine on E. coli biofilms. Int. J. Antimicrob. Agents 22(Suppl 2): 95-100.
57. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. 2011. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J. Antimicrob. Chemother. 66:946 -947.